Kraig Biocraft Laboratories, Inc. KBLB
Plastic Material, Synth Resin/Rubber, Cellulos (No Glass) · CIK 0001413119 · Fiscal year ends 1231
Revenue
$0
Fiscal year ended 2021-06-30Operating income
-$705.18K
Fiscal year ended 2021-06-30Free cash flow
—Unavailable
Fiscal year ended 2021-06-30Kraig Biocraft Laboratories, Inc. (KBLB) reported revenue of $0 and net income of -$2.75M for the fiscal year ended 2021-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Kraig Biocraft Laboratories, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Plastic Material, Synth Resin/Rubber, Cellulos (No Glass).
Income
Kraig Biocraft Laboratories, Inc. income by fiscal year, in US dollars, normalized from SEC filings.| Metric | 2021-06-30 | 2020-06-30 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 |
|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $140.76K | $152.23K | $108.63K | $70.10K |
|---|
| Cost of revenue | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Gross profit | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Operating income | -$705.18K | -$470.33K | -$1.06M | -$335.24K | -$412.01K | -$432.52K | -$147.95K | -$152.93K | -$226.56K | -$251.07K |
|---|
| Net income | -$2.75M | -$568.80K | -$1.13M | -$402.50K | -$477.75K | -$494.48K | -$206.98K | -$188.59K | -$278.93K | -$298.83K |
|---|
| Research & development | $44.73K | $32.97K | $43.99K | $20.94K | $22.30K | $56.83K | $20.22K | $50.89K | $20.13K | $67.90K |
|---|
| Weighted-average diluted shares | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Pretax income | -$2.75M | -$568.80K | -$1.13M | -$402.50K | -$477.75K | -$494.48K | -$206.98K | -$188.59K | -$278.93K | -$298.83K |
|---|
| Income tax expense | —Unavailable | —Unavailable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
|---|
| Diluted EPS | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Selling, general & administrative | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| General & administrative | $369.31K | $348.28K | $826.57K | $122.19K | $117.97K | $111.23K | $123.70K | $99.29K | $181.65K | $95.24K |
|---|
| Selling & marketing | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
Balance
Kraig Biocraft Laboratories, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.| Metric | 2021-06-30 | 2020-06-30 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 |
|---|
| Cash & equivalents | —Unavailable | —Unavailable | $283.15K | $674.23K | $907.65K | $13.70K | $22.34K | $34.44K | $48.52K | $18.15K |
|---|
| Total assets | $4.09M | $586.15K | $898.61K | $1.28M | $1.11M | $71.38K | $180.61K | $213.44K | $159.85K | $114.50K |
|---|
| Current assets | $3.67M | $63.18K | $295.82K | $709.47K | $912.80K | $20.56K | $122.96K | $152.90K | $93.98K | $48.49K |
|---|
| Total liabilities | $9.10M | $6.90M | $5.50M | $5.34M | $4.76M | $4.53M | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Current liabilities | $8.75M | $6.44M | $4.90M | $4.70M | $4.42M | $4.53M | $4.15M | $3.98M | $3.74M | $3.49M |
|---|
| Total equity incl. NCI | -$5.02M | -$6.31M | -$4.61M | -$4.07M | -$3.65M | -$4.46M | -$3.97M | -$3.76M | -$3.58M | -$3.38M |
|---|
| Temporary (mezzanine) equity | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Inventory | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Accounts receivable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | $99.26K | $114.00K | $40.99K | $25.87K |
|---|
| Goodwill | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Long-term debt | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Accounts payable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
Cash flow
Kraig Biocraft Laboratories, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.| Metric | 2021-06-30 | 2020-06-30 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 |
|---|
| Operating cash flow | —Unavailable | —Unavailable | -$314.11K | -$230.42K | -$225.05K | -$65.64K | -$28.21K | -$62.78K | -$78.37K | -$79.27K |
|---|
| Capital expenditures | —Unavailable | —Unavailable | $72.97K | $0 | $0 | $0 | $3.89K | $1.30K | $6.26K | $7.00K |
|---|
| Investing cash flow | —Unavailable | —Unavailable | -$72.97K | $0 | $0 | $0 | -$3.89K | -$1.30K | -$6.26K | -$7.00K |
|---|
| Financing cash flow | —Unavailable | —Unavailable | -$4.00K | -$3.00K | $1.12M | $57.00K | $20.00K | $50.00K | $115.00K | $30.00K |
|---|
| Net change in cash | —Unavailable | —Unavailable | -$391.08K | -$233.42K | $893.95K | -$8.64K | -$12.10K | -$14.09K | $30.37K | -$56.27K |
|---|
| Stock-based compensation | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Common dividends paid | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Common share repurchases | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Depreciation & amortization | —Unavailable | —Unavailable | $9.04K | $6.74K | $6.66K | $6.82K | $6.77K | $6.64K | $6.40K | $6.17K |
|---|
Derived
Kraig Biocraft Laboratories, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.| Metric | 2021-06-30 | 2020-06-30 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 |
|---|
| Free cash flow | —Unavailable | —Unavailable | -$387.08K | —Unavailable | —Unavailable | -$65.64K | -$32.10K | -$64.09K | -$84.63K | -$86.27K |
|---|
| Gross margin | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Operating margin | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | -105.1% | -100.5% | -208.6% | -358.2% |
|---|
| FCF margin | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | -22.8% | -42.1% | -77.9% | -123.1% |
|---|
| SBC / revenue | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Current ratio | 0.42x | 0.01x | 0.06x | 0.15x | 0.21x | 0.00x | 0.03x | 0.04x | 0.03x | 0.01x |
|---|
| Revenue YoY growth | —Unavailable | —Unavailable | -100.0% | -100.0% | -100.0% | -100.0% | 417.1% | —Unavailable | —Unavailable | 431.6% |
|---|
| Net margin | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | -147.0% | -123.9% | -256.8% | -426.3% |
|---|
| R&D / revenue | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | 14.4% | 33.4% | 18.5% | 96.9% |
|---|
| CapEx / revenue | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | 2.8% | 0.9% | 5.8% | 10.0% |
|---|
| Long-term debt / equity | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
| Effective tax rate | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable | —Unavailable |
|---|
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open KBLB in the interactive workspace to inspect any figure back to its filing.
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.